7.75 USD
↗ 0.11 (1.44%)AT CLOSE (11:59 AM EDT)
Kyverna Therapeutics, Inc. Common Stock (KYTX) trades at $7.76 per share. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics suggest KYTX is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Aug 6, 2026.